CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,953,260
- in 5 filings, $6.0M under 10b5-1 plans
Net −$5,953,260. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-04 | Hunt Anthony Chief Executive Officer | Shares withheld for taxes | −1,111 | $193.99 | $216K | 212,097 |
| 2024-03-04 | Gebski Christine See Remarks | Shares withheld for taxes | −131 | $193.99 | $25K | 28,139 |
| 2024-03-04 | Bylund James Chief Operating Officer | Shares withheld for taxes | −197 | $193.99 | $38K | 22,263 |
| 2024-03-04 | KURIYEL RALF Senior VP, R&D | Shares withheld for taxes | −135 | $193.99 | $26K | 26,892 |
| 2024-03-04 | Gebski Christine See Remarks | Shares withheld for taxes | −461 | $192.71 | $89K | 28,270 |
| 2024-03-01 | Bylund James Chief Operating Officer | Grant or award | +50 | 22,460 | ||
| 2024-03-01 | KURIYEL RALF Senior VP, R&D | Shares withheld for taxes | −453 | $191.79 | $87K | 27,027 |
| 2024-03-01 | Hunt Anthony Chief Executive Officer | Shares withheld for taxes | −3,322 | $191.79 | $637K | 213,208 |
| 2024-03-01 | Gebski Christine See Remarks | Shares withheld for taxes | −447 | $191.79 | $86K | 28,731 |
| 2024-03-01 | Bylund James Chief Operating Officer | Shares withheld for taxes | −820 | $191.79 | $157K | 22,410 |
| 2024-02-29 | KURIYEL RALF Senior VP, R&D | Grant or award | +404 | 27,480 | ||
| 2024-02-29 | Hunt Anthony Chief Executive Officer | Grant or award | +2,504 | 216,530 | ||
| 2024-02-29 | Gebski Christine See Remarks | Grant or award | +391 | 29,178 | ||
| 2024-02-29 | Bylund James Chief Operating Officer | Grant or award | +404 | 23,230 | ||
| 2024-02-27 | Bylund James Chief Operating Officer | Grant or award | +8,691 | 22,826 | ||
| 2024-02-27 | Bylund James Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +8,632 | 8,632 | ||
| 2024-02-27 | Hunt Anthony Chief Executive Officer | Grant or award | +19,719 | 214,026 | ||
| 2024-02-27 | Hunt Anthony Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +19,585 | 19,585 | ||
| 2024-02-27 | KURIYEL RALF Senior VP, R&D | Grant or award | +3,520 | 27,076 | ||
| 2024-02-27 | KURIYEL RALF Senior VP, R&D | Grant or award · Stock Option (Right to Buy) | +3,497 | 3,497 |
Page 13 of 23 · 455 trades